Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
8 Results Found
3 Ways GLP-1 Drugs Could Impact Your Hospital’s Future
Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand. Overall, the GLP-1 market is expected to experience annual growth exceeding 20% and will hit $133 billion worldwide by 2030, according to a MarketWatch report from February.
CVS Health Upends the Diabetes Drug Market
With rising prices for insulin and the costs of many other diabetes-related drugs taking their toll on patients, CVS Health recently announced that its pharmacy benefits management unit CVS Caremark is launching a program to enable employers and payers to offer these medications at no out-of-pocket costs to members.
Civica Rx Aims to Disrupt Generic Insulin Market Pricing by 2024
Pending federal approval, Civica Rx, the nonprofit consortium of U.S. hospitals, plans to manufacture and distribute several generic insulins, continuing its mission to alleviate chronic shortages of inpatient drugs and reduce drug prices.
Walmart Is Rolling Back Prices . . . This Time on Insulin
As patients and politicians continue searching for remedies to soaring insulin prices for diabetes patients, Walmart recently launched the first private-label version of the drug at less than half the price of brand-name versions.
Civica Rx Gets More Backing in Effort to Reduce Drug Prices and Shortages
The state of California put up $50 million to have Civica Rx manufacture and distribute low-cost biosimilars for the three most used short- and long-acting insulins.
Mark Cuban Plots Next Move to Collaborate with Hospitals on Drug Shortages
Billionaire entrepreneur Mark Cuban had a simple mission when he established his Cost Plus Drugs venture in 2020 — to provide low-cost, high-quality pharmaceuticals to consumers.
Latest Morgan Health Investments Signal the Company’s Focus
Morgan Health, JPMorgan Chase’s health care venture arm, has been busy making good on its pledge to invest $250 million in health care startups to help reshape health care. The company recently invested $20 million in LetsGetChecked, which offers at-home diagnostic and genetic testing, virtual appointments and prescription drug delivery.
3 Ways Pharma Could Jolt Health Care in 2023
The market for biosimilar drugs to treat cancer, inflammatory diseases, diabetes and more will continue to expand, ideally resulting in lower prices as more pharmaceutical patents expire and competitors enter the market.